1 **Hybrid nanosystems based on natural polymers as protein carriers for respiratory**
2 **delivery: Stability and toxicological evaluation**

Susana Rodrigues^a, Clara Cordeiro^{b,c,d}, Begoña Seijo^e, Carmen Remuñán-López^e, Ana Grenha^{a}*

^aCBME – Centre for Molecular and Structural Biomedicine / IBB – Institute for Biotechnology and Bioengineering, University of Algarve, Faculty of Sciences and Technology, Campus de Gambelas, 8005-139 Faro, Portugal;

^bFaculty of Sciences and Technology, University of Algarve, Campus de Gambelas, 8005-139 Faro, Portugal;

^cCEAUL- Center of Statistics and Applications, Faculty of Sciences, University of Lisbon, Campo Grande, 1749-016 Lisboa, Portugal;

^dCESUALg- Centre for research and development in Health, University of Algarve, Portugal;

^eNanoBioFar Group, Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela, Campus Vida, 15782 Santiago de Compostela, Spain

Author e-mails (per order): susananasus@gmail.com, ccordei@ualg.pt, mbegona.seijo@usc.es, mdelcarmen.remunan@usc.es, amgrenha@ualg.pt

*Corresponding author:

E-mail address: amgrenha@ualg.pt

Postal address: Centre for Molecular and Structural Biomedicine (CBME), Faculty of Sciences and Technology, Building 8, Room 3.1, Campus de Gambelas, 8005-139 Faro, Portugal; *Phone:* +351 289800100 - Ext. 7441; *Fax:* +351 289 818419

Abstract

Chitosan/carrageenan/tripolyphosphate nanoparticles were previously presented as holding potential for an application in transmucosal delivery of macromolecules, with tripolyphosphate demonstrating to contribute for both size reduction and stabilisation of the nanoparticles. This work was aimed at evaluating the capacity of the nanoparticles as protein carriers for pulmonary and nasal transmucosal delivery, further assessing their biocompatibility pattern regarding that application. Nanoparticles demonstrated stability in presence of lysozyme, while freeze-drying was shown to preserve their characteristics when glucose or sucrose were used as cryoprotectants. Bovine serum albumin was associated to the nanoparticles, which were successfully microencapsulated by spray-drying to meet the aerodynamic requirements inherent to pulmonary delivery. Finally, a satisfactory biocompatibility profile was demonstrated upon exposure of two respiratory cell lines (Calu-3 and A549 cells) to the carriers. A negligible effect on cell viability along with no alterations on transepithelial electrical resistance and no induction of inflammatory response were observed.

Keywords: biocompatibility; microencapsulation; nanoparticles; nasal delivery; protein delivery; pulmonary delivery

1. Introduction

Several physicochemical and biopharmaceutical issues make systemic administration of biomolecules a challenging task (Gupta & Sharma, 2009), compelling the need to develop adequate drug delivery systems that overcome inherent limitations. These carriers are mainly developed to avoid the need of parenteral administration, instead permitting effective transmucosal delivery. The pulmonary and nasal routes are increasingly addressed in this context, because of the large absorptive surface and the easy access, respectively, among other characteristics. Carriers are thus designed to exhibit characteristics that improve the epithelial contact, while protecting sensitive bioactive materials from *in vivo* degradation. Nanoparticles are first-line candidates for this end, successfully associating therapeutic macromolecules (Pinto Reis, Neufeld, Ribeiro & Veiga, 2006). A previous study demonstrated the ability of two natural polymers, chitosan (CS) and κ -carrageenan (CRG), to assemble into nanoparticles of 400-600 nm by simple polyelectrolyte complexation (Grenha et al., 2010). While CS is a very well-known material, the abilities of CRG are not sufficiently explored. Apart from the advantage of using natural materials, which facilitates biocompatibility (Malafaya, Silva & Reis, 2007), the polyelectrolyte complexation between CS and CRG uses very mild conditions, occurring in hydrophilic medium (Grenha, 2012). Nevertheless, the intimate contact between the carrier and the epithelial surface that highly favours mucosal delivery of drugs is reported to be maximal for particles of 50-500 nm (Desai, Labhasetwar, Amidon & Levy, 1996; Jani, Halbert, Langridge & Florence, 1990) and strong positive surface charge (Bogataj et al., 2003; Carvalho, Bruschi, Evangelista & Gremião, 2010). Therefore, more recently we associated tripolyphosphate (TPP) to the CS/CRG nanoparticle formulation as a cross-linking agent, providing a size decrease and obtaining more stable nanoparticles (Rodrigues, Rosa da Costa & Grenha, 2012).

Notwithstanding the relevance that nanoparticles have gained in the last decade, the fact is that several limitations are still to overcome regarding their application. The inherent tendency for particle aggregation, chemical instability of polymers and early release of active substances are major problems to be addressed. In addition, as nanoparticles are usually formulated as suspensions, they are prone to microbial growth (Wu, Zhang & Watanabe, 2011). Therefore, under all aspects, the physical and chemical stability of the systems is expected to be improved if water is removed (Abdelwahed, Degobert, Stainmesse & Fessi, 2006). The shelf-life of nanoparticles is a relevant aspect of their potential application as drug delivery carriers, especially concerning the need to maintain unaltered physicochemical characteristics along time. Freeze-drying appears in this context as a very adequate choice, ensuring a soft drying procedure. The more aggressive conditions associated to freeze-drying can be softened by the use of specific protectants. These will provide the formation of a solid amorphous glass film around the nanoparticles and the immobilisation of the carriers, preventing aggregation and promoting stabilisation (Beirowski, Inghelbrecht, Arien & Gieseler, 2011, 2012).

Safety issues are another permanent subject adjacent to nanoparticle applications. **In fact, regarding the inhalation of nanoparticles, their fate after administration remains uncertain and there is the possibility of accumulation in the lung tissue upon repeated administrations (Rogueda & Traini, 2007).** With regard to the evaluation of materials safety, there is a general recommendation **considering** that an initial *in vitro* evaluation should comprise different cell lines and times of exposure, while not only cell viability but also the inflammatory response should be determined (ISO, 2009; Rodrigues, Dionísio, Remuñán-López & Grenha, 2012). The Calu-3 and A549 respiratory epithelial cell lines have been frequently used in this context to evaluate the behaviour of systems aimed at respiratory drug delivery, either nasal

or pulmonary (Foster, Avery, Yazdanian & Audus, 2000; Grenha et al., 2007; Nahar et al., 2013).

In this work, we aimed at exploring the potential of CS/CRG/TPP nanoparticles for an application in nasal and pulmonary transmucosal delivery of proteins, placing a particular emphasis on their biocompatibility behaviour. Additionally, the stability of nanoparticles in presence of lysozyme (an enzyme present in the nasal and lung mucosa), as well as the ability of freeze-drying to provide a dry form of nanoparticle suspensions, were also assessed. Regarding pulmonary administration, as nanoparticles are known to lack the adequate aerodynamic diameter to permit deep lung delivery with success, which should vary between 1 and 5 μm , the strategy of microencapsulating the nanocarriers was applied, following a previously described approach (Grenha, Seijo & Remuñán-López, 2005).

2. Materials and Methods

2.1. Materials

Chitosan (low molecular weight, deacetylation degree = 75-85%), pentasodium tripolyphosphate, bovine serum albumin (BSA), phosphate buffer saline (PBS) tablets pH 7.4, Dulbecco's modified Eagle's medium (DMEM), penicillin/streptomycin (10000 units/mL, 10000 $\mu\text{g/mL}$), non-essential amino acids, L-glutamine 200 mM, trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), trypan blue solution (0.4%), thiazolyl blue tetrazolium bromide (MTT), sodium dodecyl sulphate (SDS), *N,N*-dimethylformamide (DMF), glycerol, lipopolysaccharide (LPS), dimethyl sulfoxide (DMSO), lysozyme and glacial acetic acid were supplied by Sigma Chemicals (Germany). *k*-carrageenan was obtained from FMC Biopolymer (Norway) and fetal bovine serum (FBS) was from Gibco (USA). Ultrapure water (Milli-Q Plus, Millipore Iberica, Spain) was used throughout.

2.2 Cell lines

The Calu-3 and A549 cell lines were obtained from the American Type Culture Collection (Rockville, USA) and used between passages 35–45 and 20–30, respectively. Cell cultures were grown in 75 cm² flasks in a humidified 5% CO₂/95% atmospheric air incubator at 37 °C. For both cell lines, cell culture medium (CCM) was DMEM supplemented with 10% (v/v) FBS, 1% (v/v) non-essential amino acids solution, 1% (v/v) L-glutamine solution (200 mM) and 1% (v/v) penicillin/streptomycin. Medium was exchanged every 2–3 days and cells were subcultured weekly in the case of A549 cells and every 10 to 15 days for Calu-3 cell line.

2.3. Preparation of CS/CRG/TPP nanoparticles

CS/CRG/TPP nanoparticles were prepared as described previously (Rodrigues, Rosa da Costa & Grenha, 2012) based on the polyelectrolyte complexation of CS with CRG and additional ionic gelation of chitosan with TPP anions. After an initial optimisation, a final theoretical CS/CRG/TPP ratio of 4/1/1 (w/w) was selected to perform the studies (4/1/0 for control nanoparticles). Briefly, CS was dissolved in 1% (w/w) acetic acid to obtain a solution of 1 mg/mL. CRG and TPP were dissolved in purified water and mixed to obtain a solution where the concentration of each polymer is 0.63 mg/mL. The spontaneous formation of nanoparticles occurs upon incorporation of 0.8 mL of a solution of CRG/TPP or CRG into 2 mL of the CS solution, under gentle magnetic stirring at room temperature.

The association of BSA to the nanoparticles was performed by dissolving the protein in water and mixing with a previously prepared mixture of CRG/TPP solution, prior to the addition to CS solution, as described above. The amount of BSA associated to each batch was calculated to represent a theoretical content of 30% (w/w) of the amount of CS.

Nanoparticles were concentrated by centrifugation at 16,000 x g on a 10 µL glycerol layer for 30 min at 15 °C (Heraeus Fresco 17 centrifuge, Thermo scientific, USA). After discarding the supernatants, the nanoparticles were resuspended in 200 µl of purified water.

When no further indication is provided, ‘CS/CRG/TPP nanoparticles’ refer to mass ratios 4/1/1.

2.4. Characterisation of nanoparticles

2.4.1. Determination of production yield

The nanoparticle production yield was calculated by gravimetry. Fixed volumes of nanoparticle suspensions were centrifuged (16,000 x g, 30 min, 15 °C), and sediments were freeze-dried over 24 h at -34 °C, followed by a gradual increase in temperature until 20 °C, using a Labconco freeze dryer (Labconco, USA) (*n* = 3). The yield of nanoparticle production (PY) was calculated as follows:

$$PY = (\text{Nanoparticle sediment weight} / \text{Total solids weight}) \times 100 \quad (1)$$

where nanoparticle sediment weight is the weight after freeze-drying and total solids weight is the total amount of solids added for nanoparticle formation.

2.4.2. Morphological observation

The morphological examination of CS/CRG/TPP nanoparticles was conducted by transmission electron microscopy (TEM) (JEM-1011, JEOL, Japan). The samples were stained with 2% (w/v) phosphotungstic acid (Carvalho, Grenha, Remunan-Lopez, Alonso & Seijo, 2009) and placed on copper grids with carbon films (Ted Pella, USA) for TEM observation.

2.4.3. Physicochemical properties

Measurements of nanoparticle size and zeta potential were performed on freshly prepared samples by photon correlation spectroscopy and laser Doppler anemometry, respectively, using a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). For the analysis of particle size and determination of the electrophoretic mobility, each sample was diluted to the appropriate concentration with ultrapure water and placed in the electrophoretic cell. Each analysis was performed at 25 °C. Three batches of each formulation were analysed ($n = 3$).

2.4.4. Determination of BSA association capacity

The amount of non-encapsulated BSA was determined in the supernatant by reverse phase - high performance liquid chromatography (RP-HPLC; Agilent 1100 series, Germany). The chromatographic conditions were adapted from Umrethia et al. (Umrethia, Kett, Andrews, Malcolm & Woolfson, 2010) as follows: Aeris widepore 3.6u XB-C18 300A column 4.6 mm i.d.×250 mm length with security guard cartridge (Phenomenex, UK); run temperature 25 °C; gradient flow (0.1% TFA in water (A), 0.1% TFA in acetonitrile (B); A/B from 95:5 to 35:65 in 10 min) mobile phase, total run time 15 min, UV detection at 280 nm; flow rate 1.0 mL/min; injection volume 20 µL; BSA retention time 8.8 min. A linear calibration plot for BSA in the different solvents (acetic acid solution, PBS pH 7.4 and buffer pH 6.8) was obtained over the range 10-120 µg/mL ($n = 3$). BSA association efficiency (AE) and nanoparticle loading capacity (LC) were calculated as follows:

$$AE = (\text{Total amount of BSA} - \text{Free amount of BSA}) / \text{Total amount of BSA} \times 100 \quad (2)$$

$$LC = (\text{Total amount of BSA} - \text{Free amount of BSA}) / \text{Nanoparticle weight} \times 100 \quad (3)$$

2.5. Evaluation of nanoparticle stability in the presence of lysozyme

The stability of CS/CRG/TPP nanoparticles (4/1/0 and 4/1/1) was analysed in presence of lysozyme. To do so, nanoparticle suspensions at a concentration of 1 mg/mL were incubated

with lysozyme (0.2 and 0.8 mg/mL) (Grenha, Seijo & Remuñán-López, 2005) at 37 °C under mild horizontal shaking, for 120 min. At appropriate time intervals (30, 60, 90 and 120 min), the size and zeta potential of nanoparticles were measured, as described above ($n = 3$).

2.6. Nanoparticle stability upon freeze-drying

With the aim of developing a pharmaceutically-acceptable dry form of the nanoparticle suspensions, CS/CRG/TPP nanoparticles were submitted to a freeze-drying study. Different concentrations of nanoparticles (1, 2 and 4 mg/mL) and different cryoprotectants (trehalose, lactose, sucrose and glucose) at varied concentrations were tested as variables in the optimisation of nanoparticle stabilisation by freeze-drying. To perform the study, 1 mL of unloaded nanoparticles was freeze-dried in the presence of 5 or 10% (w/v) of cryoprotectant. The freeze-drying process occurred at a pressure of 50–100 Torr and consisted of 24 h of primary drying, starting at -35 °C and gradually increasing to -10 °C, 24 h at 0 °C and a final step of secondary drying (12–24 h) at 15 °C (Labconco Corp., USA). After freeze-drying, nanoparticle suspensions were reconstituted by adding the volume of water corresponding to the initial volume (1 mL), and their size and zeta potential were determined as indicated above ($n = 3$).

The conditions found to better maintain the original properties of unloaded nanoparticles were applied on BSA-loaded nanoparticles. In this case, nanoparticle concentrations of 1 and 2 mg/mL were freeze-dried with both glucose and sucrose at a concentration of 10% (w/w).

2.7. Preparation of microencapsulated nanoparticles

Mannitol was selected as matrix material for the production of microparticles, as was previously described (Grenha, Seijo & Remuñán-López, 2005). An aqueous solution of the excipient was prepared at a concentration of 1.6% (w/v). Upon centrifugation, CS/CRG/TPP

nanoparticles were resuspended with the mannitol solution instead of water, in order to obtain a mannitol/nanoparticle ratio of 80/20 (w/w). The final solid concentration of the suspensions was 2% (w/v).

Dry powders were obtained by spray-drying the previously prepared suspension using a laboratory-scale spray-dryer (Buchi® Mini Spray Dryer, B-290, Buchi, Switzerland).

The spray-drying conditions were: feed rate of 2.5 mL/min, two fluids external nozzle 0.7 mm, inlet temperature of 160 ± 2 °C, outlet temperature of 95 ± 3 °C. The airflow rate and the aspirator were kept constant at 400 NI/h and 80%, respectively. The spray-dried powders were collected and stored in a desiccator at room temperature until use.

2.8. Characterisation of microencapsulated nanoparticles

2.8.1. Determination of spray-drying yield

The spray-drying yield was calculated by gravimetry, comparing the total amount of solids initially added for the preparation of microencapsulated nanoparticles (CS + CRG + TPP + BSA + mannitol) with the amount of resulting microspheres ($n = 3$). The following equation was used for the calculation:

$$\text{Yield (\%)} = \frac{\text{Microspheres weight}}{\text{Total solids weight}} \times 100 \quad (4)$$

2.8.2. Morphological and aerodynamic characterisation

The morphological characterisation of microspheres was performed using a field emission scanning electron microscope (FESEM; FESEM Ultra Plus, Zeiss, Germany) at 3 kV of voltage, which is equipped with a secondary electron (SE) detector. The dry powders were placed onto metal plates and a 5 nm thick gold palladium film was sputter-coated on the samples (Q150T S/E/ES Sputter Coater, Quorum Technologies, UK) before viewing.

218 The particle size was estimated as the Feret's diameter (distance between two tangents on
219 opposite sides of the particles) and was directly determined with an optical microscope
220 (Olympus IX51, Japan). The estimation was based on the mean diameter resulting from the
221 evaluation of 300 particles ($n = 300$).

222 Real density was determined using a Helium Pycnometer (Micropycnometer, Quanta
223 Chrome, model MPY-2, USA) ($n = 3$). Apparent tap density was obtained by measuring the
224 volume of a known weight of powder in a 10 mL test-tube after mechanical tapping (30
225 tap/min, Tecnociencia, Spain). After registration of the initial volume, the test-tube was
226 submitted to tapping until constant volume was achieved, according to a previously described
227 method (El-Gibaly, 2002) ($n = 3$).

228 The aerodynamic diameter was obtained using a TSI Aerosizer[®] LD equipped with an
229 Aerodisperser[®] (Amherst Process Instrument Inc.; Amherst, MA, USA) and assuming real
230 density as the density parameter for the determination of the aerodynamic diameter.

231

232 **2.9. *In vitro* biocompatibility study**

233 *2.9.1. Evaluation of metabolic activity*

234 The *in vitro* cytotoxicity of CS/CRG/TPP nanoparticles, microencapsulated nanoparticles
235 (mannitol/nanoparticles = 80/20, w/w), as well as that of the raw materials involved in
236 nanoparticle production, was assessed by the metabolic assay thiazolyl blue tetrazolium
237 bromide (MTT) test. Two cell lines representative of pulmonary and nasal epithelia (Calu-3
238 and A549 cells) were used. A549 cells were seeded at a density of 1×10^4 cells/well and Calu-
239 3 cells at 2×10^4 cells/well in 96-well plates, in 100 μ l of the same medium used for culture in
240 cell culture flasks. The cells were grown at 37 °C in a 5% CO₂ atmosphere for 24 h before
241 use (Grenha et al., 2007).

Three different concentrations (0.1, 0.5 and 1.0 mg/mL) of nanoparticles were evaluated for cytotoxicity over 3 and 24 h. Suspensions of unloaded nanoparticles and microencapsulated nanoparticles, BSA loaded nanoparticles and solutions of the individual raw materials (CS, CRG and TPP) were evaluated separately for cytotoxicity. Sodium dodecyl sulphate (SDS, 2%, w/v) was used as a positive control of cell death. Optimal cell seeding density and the absence of MTT conversion in the assay medium were confirmed in preliminary experiments. All formulations and controls were prepared as solution/suspensions in pre-warmed CCM without FBS immediately before application to the cells.

To initiate the assay, culture medium of cells at 24 h in culture was replaced by 100 µL of fresh medium without FBS containing the test samples or controls. After 3 or 24 h of cell incubation, samples/controls were removed and 30 µL of the MTT solution (0.5 mg/mL in PBS, pH 7.4) were added to each well. After 2 h, any generated formazan crystals were solubilised with 50 µL of DMSO. Upon complete solubilisation of the crystals, the absorbance of each well was measured by spectrophotometry (Infinite M200, Tecan, Austria) at 540 nm and corrected for background absorbance using a wavelength of 650 nm (Carmichael, DeGraff, Gazdar, Minna & Mitchell, 1987).

The relative cell viability (%) was calculated as follows:

$$\text{Viability (\%)} = (A - S) / (CM - S) \times 100 \quad (6)$$

where A is the absorbance obtained for each of the concentrations of the test substance, S is the absorbance obtained for the 2% SDS and CM is the absorbance obtained for untreated cells (incubated with CCM). The latter reading was assumed to correspond to 100% cell viability. The assay was performed on three occasions with six replicates at each concentration of test substance in each instance.

2.9.2. Determination of inflammatory response

The inflammatory response generated by the exposure to nanoparticles and microencapsulated nanoparticles was evaluated on Calu-3 cells. To perform the assay, the cells were seeded on 96-well plates (2×10^4 cells/well) and, after 24 h incubation at 37 °C in 5% CO₂ atmosphere, exposed to nanoparticles and microencapsulated nanoparticles at a concentration of 1 mg/mL. The exposure to lipopolysaccharide (LPS; 10 µg/mL) was used as positive control (Alfaro-Moreno et al., 2009; Mura et al., 2011), while cells incubated with CCM were used as negative control. All formulations and controls were prepared as solutions/suspensions in pre-warmed CCM without FBS immediately before application to the cells. After 24 h of exposure, the cell supernatants were collected and centrifuged (10 min, 16,000 x g, 15 °C, centrifuge 5804R, Eppendorf, Germany). The levels of IL-6 and IL-8 existing in Calu-3 cell supernatants were determined by quantitative ELISA using human IL-6 and IL-8 Quantikine ELISA kits (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. The supernatants were appropriately diluted (approximately 10 times for IL-6 and 50 times for IL-8). The assay was performed on three occasions with two replicates of test substance in each instance. The concentration of individual cytokines for each sample is expressed as percentage of the control (incubation with CCM) from triplicate assays.

2.9.3. Evaluation of epithelial integrity

For the studies of epithelial integrity, Calu-3 cells were cultured at an air interface according to a previously described methodology (Grainger, Greenwell, Lockley, Martin & Forbes, 2006). Briefly, 100 µL of Calu-3 cell suspension was seeded at a density of 5×10^5 cells/cm² in Transwell inserts (0.33cm²), with 0.5 mL medium in the basolateral chamber. The cells were incubated at 37 °C, 5% CO₂ for 2 days. After this time, the medium was aspirated from the apical and basolateral chambers and replaced only in the basolateral chamber, the apical

chamber being exposed to the incubator atmosphere. Medium was replaced every 2 days thereafter.

In order to verify the effect of nanoparticles on Calu-3 cell layer integrity, the formulations were dispersed in 100 μ L FBS-free CCM at a concentration of 1 mg/mL and incubated with the cell layers. Transepithelial electrical resistance (TER) was measured using chopstick electrodes and an EVOM[®] volt meter (STX-2 and Evom G, World Precision Instruments, UK). TER measurements were taken 30 min before the experiment and at 0.5, 1, 2, 4, 6, 24 and 48 h after administration. TER values were calculated by subtracting the resistance of cell-free culture inserts and correcting for the surface area of the Transwell insert. Cell layers incubated with CCM were used as the reference (control), from which TER changes during exposure to the samples were calculated. All experiments were performed in triplicate on three occasions.

2.10. Statistical analysis

For the generality of results, the *t*-test and the one-way analysis of variance (ANOVA) with the pairwise multiple comparison procedures (Dunn's Method) were performed to compare two or multiple groups, respectively.

The freeze-drying case study determines the effect of different cryoprotectants and nanoparticle concentration on nanoparticle stability. Due to the number of observations involved (three to four) in each cell/treatment and to the existence of empty cells, a more complex statistical methodology was not applied, because it would compromise the model assumptions and result in misleading inferences. Therefore, the statistical approach used for this analysis was the one-way ANOVA with Gowes-Howell post-hoc tests, based on sample sizes and variance homogeneity between groups.

The factorial design (FD) is often used for manipulative experiments, such as that of the metabolic activity (MTT test). In that case, for both cell lines tested (Calu-3 and A549) the effect of sample type (X_1) and concentration (X_2) on cell viability (Y). Each of the factors (X_1 and X_2) has three levels. In the case of X_2 the levels are 0.1, 0.5 and 1.0 mg/mL. For X_1 there is a split in two groups: 1) when raw materials are considered the levels of X_1 are CS, CRG and TPP; 2) when carrier formulations are studied, the levels are unloaded nanoparticles, BSA-loaded nanoparticles, microencapsulated nanoparticles. For either raw materials or carrier formulations, the objective is to investigate the influence of factors X_1 and X_2 on the response variable (Y). FD was originally planned with equal number of observations per treatment, but some occurrences related to random loss of observations or to practical constraints, cause inequality of sample sizes. Therefore, for the four multifactor designs present in this study, three were unbalanced with observations in every cell/treatment. For this complex FD, the type III sum of squares (SS) was used, because it is not influenced by the sample size in each treatment. The basic multivariate assumptions to be checked are that the errors are independent, normally distributed and have constant variance. Further analyses with Post hoc tests Hochberg's GT2 (unbalanced FD) and Tukey, were used to determine which groups differ.

The statistical analyses were performed with the software SPSS (version 22.0 for windows) considering a significance level of $\alpha = 0.05$.

3. Results and discussion

CS/CRG/TPP nanoparticles were previously reported by our group in a work that evidenced the ability of TPP to decrease nanoparticle size and improve stability (Rodrigues, Rosa da Costa & Grenha, 2012). In that work, the potential of the carriers for transmucosal drug delivery was suggested. More recently we have observed the ability of these nanocarriers to

associate different proteins, demonstrating that the pH of the nanoparticle assembly medium has a strong effect on protein association and the pH of the release medium affects the release profile (unpublished results). The present work is dedicated to the study of these nanoparticles regarding an application in nasal and pulmonary delivery.

3.1. Characterisation of CS/CRG/TPP nanoparticles

After an initial screening of varied CS/CRG/TPP mass ratios, seeking for the formulation that produces nanoparticles with the most suitable characteristics for the objective of transmucosal delivery (Rodrigues, Rosa da Costa & Grenha, 2012), the formulation CS/CRG/TPP = 4/1/1 (w/w) was selected for subsequent studies. The corresponding formulation without TPP (CS/CRG/TPP = 4/1/0, w/w) was used as control in some of the performed studies to show the effect of the inclusion of TPP.

Figure 1A depicts the result of the morphological evaluation of BSA-loaded nanoparticles, which evidence a spherical structure similar to both unloaded nanoparticles (Rodrigues, Rosa da Costa & Grenha, 2012) and to polysaccharide-based nanoparticles in general (Goycoolea, Lollo, Remunan-Lopez, Quaglia & Alonso, 2009; Oyarzun-Ampuero, Brea, Loza, Torres & Alonso, 2009; Zorzi, Párraga, Seijo & Sánchez, 2011).

As shown in Table 1, the developed BSA-loaded nanoparticles evidence adequate physicochemical properties for the objective of transmucosal delivery, with a size around 300 nm and a positive zeta potential (+40 mV). In fact, the size is small enough to permit an intimate contact with epithelial surfaces, **which is maximal at 50 – 500 nm** (Desai, Labhasetwar, Amidon & Levy, 1996; Jani, Halbert, Langridge & Florence, 1990). In turn, the high positive zeta potential further potentiates the interaction with epithelia, as this is negatively charged and, thus, an electrostatic interaction is enabled. In summary, these characteristics are expected to provide a prolonged retention of nanoparticles close to

epithelial surfaces, potentiating protein release. Notwithstanding the importance of these physicochemical features, the presence of mucus and the mechanism of mucociliary clearance also need to be considered regarding the success of nasal and pulmonary transmucosal delivery (Dombu & Betbeder, 2013; Martin, Schipper, Verhoef & Merkus, 1998). Nanoparticles described in this work are expected to exhibit bioadhesive properties to some extent, due to the chitosan content. Besides the proper chitosan ability to adhere to biological substrates (Du, Cai & Zhai, 2014; Lehr, Bouwstra, Schacht & Junginger, 1992), chitosan-based nanoparticles have also demonstrated the same capacity in several occasions (Bernkop-Schnürch, Weithaler, Albrecht & Greimel, 2006; Sandri, Bonferoni, Rossi, Ferrari, Boselli & Caramella, 2010). This will possibly improve the carrier residence time close to the epithelia, potentiating drug absorption (Dombu & Betbeder, 2013; Martin, Schipper, Verhoef & Merkus, 1998). Additionally, nanoparticles have been reported to avoid or delay mucociliary clearance, although this ability is highly dependent on their size and is more relevant for particles below 100 nm (Oberdörster, Oberdörster & Oberdörster, 2005; Sung, Pulliam & Edwards, 2007).

It is also observed in the table that the inclusion of TPP in the formulation increases the nanoparticle production yield, while maintaining the encapsulation efficiency, which is around 50%. A great difference is observed in loading capacity, which is of 70% for CS/CRG/TPP = 4/1/0 and approximately 30% for 4/1/1. This difference is explained by the fact that, while both formulations encapsulate a similar amount of protein, the nanoparticles containing TPP display a considerably higher production yield. Therefore, as viewed in Eq. 3, there is the same amount of protein distributed by a higher amount of total solids, thereby resulting in a lower value of loading capacity. Unloaded nanoparticles display somewhat different physicochemical characteristics, 4/1/0 nanoparticles having 491 nm and +78 mV and 4/1/1 nanoparticles displaying a size of 208 nm and +47 mV (data not shown).

3.2. Evaluation of nanoparticle stability in presence of lysozyme

Lysozyme is an enzyme that is present in mucosal surfaces, including the nasal and pulmonary (Konstan, Chen, Sherman, Thomassen, Woodm & Boat, 1981; Muzzarelli, 1997), which exhibits the ability to cleave β -(1-4) glycosidic bonds of chitosan (Muzzarelli, 1997). Therefore, taking into account the high content of chitosan present in the proposed nanoparticles, evaluating their behaviour in presence of this enzyme is important regarding a future interpretation of results, such as those obtained *in vivo*. To perform the evaluation, nanoparticles were incubated with lysozyme (0.2 and 0.8 mg/mL) at 37 °C and their size and zeta potential were monitored along time. The enzyme concentration of 0.2 mg/mL was used taking into account indications found in the literature regarding physiological concentrations of the enzyme (Konstan, Chen, Sherman, Thomassen, Woodm & Boat, 1981). Furthermore, a concentration of 0.8 mg/mL was chosen to investigate the nanoparticle behaviour in extreme conditions, as previously reported (Grenha, Seijo & Remuñán-López, 2005).

As observed in Figure 2, the formulation of nanoparticles without TPP (CS/CRG) showed a tendency for size decrease along time. When lysozyme was present at a concentration of 0.2 mg/mL, the decrease was not significant, as high standard deviations are obtained. However, at 0.8 mg/mL a strong and significant size decrease ($p < 0.05$) occurs up to 60 min of incubation, although after that a sudden increase in size is observed, inverting the trend. This is probably due to aggregation, as a concomitant increase in the standard deviation of the mean size is observed, indicating a great dispersion of sizes. Zeta potential, in turn, remained stable during the assay (data not shown). Interestingly, the formulation containing TPP was not affected by the presence of the enzyme, no significant size reduction being observed independently of the concentration of lysozyme. This behaviour reveals a somewhat protecting effect attributed by TPP.

An absence of effect of the enzyme on chitosan-based nanoparticles (also containing TPP) incubated in similar conditions was previously reported in another study (Vila, Sánchez, Tobío, Calvo & Alonso, 2002). It is possible that the inclusion of TPP, which acts as cross-linker, prevents or at least modifies chitosan exposure, thus not enabling an easy and rapid enzymatic degradation as is seen for nanoparticles devoid of TPP.

3.3. Evaluation of nanoparticle stability upon freeze-drying

When nanocarriers are formulated as aqueous suspensions, both physical (aggregation/particle fusion) and chemical (hydrolysis of polymer and chemical reactivity) instability phenomena are known to appear at some point (Abdelwahed, Degobert, Stainmesse & Fessi, 2006; Chacón, Molpeceres, Berges, Guzmán & Aberturas, 1999; Kumar, Shafiq & Malhotra, 2012), limiting nanoparticle applications (Sameti et al., 2003; Wu, Zhang & Watanabe, 2011). Aqueous suspensions of CS/CRG/TPP nanoparticles were reported in a previous work to remain stable for up to 9 months, the presence of TPP in the formulation demonstrating to have a significant role in this effect (Rodrigues, Rosa da Costa & Grenha, 2012). However, the preference in storing and transporting products in dry state, has led to the decision of developing a lyophilised formulation. Regarding the present work, it is important to recall that a nasal formulation of nanoparticles will involve a suspension, while microencapsulated nanoparticles (dry powders) are proposed for lung delivery. Still, in the latter case there might be a time period between nanoparticle production and microencapsulation where a lyophilized form of nanoparticles will be beneficial for storage. Freeze-drying has been considered an adequate technique to improve the long-term stability of colloidal nanoparticles. Nevertheless, it is a complex process that requires a major optimisation of the inherent conditions. Many parameters of the formulation/process may decide the success of freeze-drying (Abdelwahed, Degobert, Stainmesse & Fessi, 2006). In

440 this study, nanoparticles were freeze-dried using different sugars as cryoprotectants, at varied
441 concentrations. The concentration of nanoparticle suspensions was also tested as variable.
442 The direct freeze-drying of nanoparticles (without cryoprotectants) did not permit the
443 preservation of their properties (data not shown), leading to strong aggregation. This effect
444 might be explained by both the high concentration of particles undergoing the freezing step
445 and the mechanical stress induced by ice crystallization (Abdelwahed, Degobert, Stainmesse
446 & Fessi, 2006; Vauthier & Bouchemal, 2009). **This** observation was reported in a previous
447 work of our group **for** nanoparticles composed of other polysaccharides (Dionísio, Cordeiro,
448 Remuñán-López, Seijo, Rosa da Costa & Grenha, 2013), as well as in other works available
449 on the literature (Abdelwahed, Degobert, Stainmesse & Fessi, 2006; de la Fuente, Seijo &
450 Alonso, 2008).

451 The purpose of this study was thus examining the effects of type of cryoprotectant (sucrose,
452 trehalose, lactose and glucose), cryoprotectant concentration (5% and 10%, w/w) and
453 nanoparticle concentration (1, 2 and 4 mg/mL) on the nanoparticle characteristics upon
454 reconstitution with water from the corresponding lyophilized powder.

455 Figure 3 displays the variation of nanoparticle size when comparing the obtained value after
456 reconstitution of freeze-dried material (D_f) with that initially determined (D_i) before the
457 freeze-drying process. As a first approach, unloaded nanoparticles were used. The ANOVA
458 experiment revealed that the concentration of nanoparticle suspensions to be freeze-dried is
459 the sole parameter evidencing a relevant and statistically significant effect on the stability
460 conferred by the cryoprotectants. In this regard, the *post-hoc* test (Gowes-Howell) shows that
461 using nanoparticle concentrations of 2 mg/mL or 4 mg/mL leads to a higher increase of
462 nanoparticle size ($p < 0.05$) as compared with 1 mg/mL, which is the concentration
463 permitting the desired maintenance of size after freeze-drying.

464 Zeta potential values did not evidence alterations after freeze-drying in any of the tested
465 conditions (data not shown). Other works studying the freeze-drying of comparable
466 concentrations of polysaccharide-based nanoparticles have reported good stabilization
467 provided by the same or similar cryoprotectants (de la Fuente, Seijo & Alonso, 2008;
468 Dionísio, Cordeiro, Remuñán-López, Seijo, Rosa da Costa & Grenha, 2013; Hirsjärvi,
469 Peltonen & Hirvonen, 2009).

470 Although not to a statistically significant manner, other interpretations might be suggested by
471 Figure 3. Regarding the performance of the distinct cryoprotectants that were tested, it is
472 important to observe that lactose (a typical excipient used in lung delivery) revealed
473 absolutely inefficient as cryoprotectant agent, not preventing particle aggregation after
474 freeze-drying. This poor protective effect was also observed in a previous work of the group
475 with other polysaccharide-based nanoparticles (Dionísio, Cordeiro, Remuñán-López, Seijo,
476 Rosa da Costa & Grenha, 2013) and was further reported in the literature, being attributed to
477 an ineffective protection during the freezing step (Hirsjärvi, Peltonen & Hirvonen, 2009).

478 **Sucrose, glucose and trehalose (in this order) are** suggested to have better ability as
479 cryoprotectants, as their presence provided a more adequate maintenance of the initial
480 characteristics of nanoparticles, at least **under certain conditions. Sucrose maintained the**
481 **exact characteristics of nanoparticles when used at 10%** (with the already mentioned
482 exception of the 4 mg/mL concentration of nanoparticles) or at 5% when nanoparticles are
483 freeze-dried at the lower concentration tested. A very satisfactory cryoprotective effect
484 provided by both glucose and sucrose was previously reported by our group regarding the
485 stabilisation of two formulations of pullulan-based nanoparticles (sulfated pullulan/chitosan
486 and carrageenan/aminated pullulan) (Dionísio, Cordeiro, Remuñán-López, Seijo, Rosa da
487 Costa & Grenha, 2013). The concentration of the cryoprotectant is also an important
488 parameter to optimise. In this regard, a content of 5% was generally found to be enough to

stabilise nanoparticles freeze-dried at a concentration of 1 mg/mL, while an increase to 10% of cryoprotectant is needed when the nanoparticle concentration increases to 2 mg/mL. Considering the results obtained with unloaded nanoparticles, BSA-loaded nanoparticles at the concentration of 1 and 2 mg/mL were freeze-dried with 10% of both glucose and sucrose. The physicochemical characteristics of the nanoparticles were still maintained (data not shown). However, it was previously referred that the use of glucose as cryoprotectant of protein formulations should be cautious because of its reducing character (Li, Patapoff, Overcashier, Hsu, Nguyen & Borchardt, 1996; Wang, 2000). Nevertheless, the freeze-drying of protein nanocarriers in presence of glucose has been reported as efficient, considering both the physicochemical stability of the carrier and the maintenance of protein properties (Freixeiro et al., 2013). In any case, a comprehensive review on the subject suggests that any evaluation should be performed on a case-by-case basis (Wang, 2000). This study evidences the suitability of using freeze-drying to obtain nanoparticles in a dry form, but it reinforces the importance of carefully selecting and optimising the conditions of the freeze-drying process in order to achieve an optimised protective effect.

3.4. Microencapsulation of nanoparticles

The success of inhalable formulations is primarily dependent on their aerodynamic properties, as these influence both the dispersion and sedimentation pattern of the carriers (Sung, Pulliam & Edwards, 2007). When a systemic action is intended, the drug carriers should be small enough to pass through the mouth, throat and conducting airways and reach the deep lung, but not so small that they fail to deposit and are breathed out again. In this context, it has been considered that an aerodynamic diameter between 1 and 5 μm is necessary (Bosquillon, Lombry, Prat & Vanbever, 2001), which in some cases is even narrowed to 2-3 μm (Oberdrster, Oberdrster & Oberdrster, 2005). A specific conjugation

between size and density of the carriers is, thus, necessary. The pulmonary administration of nanoparticles is severely hindered by their low inertia, which makes alveolar deposition practically impossible, mainly resulting in the exhalation of the carriers (Sung, Pulliam & Edwards, 2007). The spray-drying of CS-based nanoparticles was first reported by Grenha et al. (2005) as a strategy to endow the nanoparticles with the ability to reach the deep lung. This strategy was later on followed by other groups (Li, Sun, Gong, Liu, Zuo & Zhang, 2010; Pourshahab, Gilani, Moazeni, Eslahi, Fazeli & Jamalifar, 2011). In the present work, the microencapsulation of CS/CRG/TPP nanoparticles was approached to obtain a drug delivery system that permitted efficient administration of the developed nanocarriers aimed at the systemic pulmonary delivery of proteins. Mannitol was selected to compose the matrix of microparticles, as it has demonstrated to simply act as carrier of nanoparticles, providing their release upon reaching the alveoli (Grenha, Seijo & Remuñán-López, 2005). Microencapsulated nanoparticles were produced by spray-drying a suspension of mannitol/nanoparticles (80/20, w/w), evidencing a spherical shape and a slightly corrugated surface, as can be observed in Figure 1B. The nanoparticle carriers were determined to have a Feret diameter of $2.3 \pm 0.6 \mu\text{m}$, a real density of $1.44 \pm 0.01 \text{ g/cm}^3$ and a tap density of $0.42 \pm 0.04 \text{ g/cm}^3$. The aerodynamic diameter was determined to be $1.80 \pm 0.11 \mu\text{m}$. Comparable results were reported for microencapsulated CS/TPP nanoparticles (Grenha, Seijo & Remuñán-López, 2005), a system that already demonstrated its efficacy *in vivo* for the administration of insulin (Al-Qadi, Grenha, Carrión-Recio, Seijo & Remuñán-López, 2012). Good indications are thus provided on the capacity of the developed system to act as carrier of nanoparticles to the lung with the aim of a systemic delivery of proteins. **Nevertheless, using this approach of microencapsulating the nanoparticles could possibly pose an extra limitation, regarding the high proportion of excipients that need to be used and, consequently, the inherent lower loading. Taking into account that administrations of around 160 – 180 mg**

of dry powder have been reported (Hoppentocht, Hagedoorn, Frijlink & de Boer, 2014; Labiris, Holbrook, Chrystyn, Macleod & Newhouse, 1999) and considering a protein loading of 27% in nanoparticles and the 20% amount of nanoparticles in the final microparticle formulation, 160 mg would carry approximately 9 mg of protein. This amount is considered suitable for the purpose of obtaining a therapeutic effect and will possible not compromise the success of the formulation, which will obviously be dependent on several other parameters.

3.5. *In vitro* biocompatibility study

Evaluating the biocompatibility of drug delivery formulations is nowadays a mandatory aspect to address (Gaspar & Duncan, 2009). While an accurate determination of the toxicity of a formulation can only be determined *in vivo*, a variety of *in vitro* toxicological assays, performed in adequately selected cell lines, might provide very useful information and are widely accepted as first indicators (ISO, 2009; Rodrigues, Dionísio, Remuñán-López & Grenha, 2012). Current international guidelines require the evaluation to be contextualised with a specific route of administration and dose of the material (Gaspar & Duncan, 2009). It is also referred that polymers and polymer-based carriers should be regarded as different entities and, thus, evaluated separately (Aillon, Xie, El-Gendy, Berkland & Forrest, 2009; Gaspar & Duncan, 2009; Williams, 2008). This is based on the assumption that the proper carrier structure, among other parameters, might affect the final toxicological behaviour (Aillon, Xie, El-Gendy, Berkland & Forrest, 2009; Gaspar & Duncan, 2009).

To address the above mentioned issues, the evaluation of the biocompatibility of CS/CRG/TPP nanoparticles and corresponding raw materials, was performed in this study by means of three different assays, 1) the metabolic activity (MTT), 2) the inflammatory response (detection of IL-6 and IL-8) and 3) the epithelial integrity (measurement of TER).

Calu-3 and A549 were the selected cell lines, as they are representative of the respiratory epithelia. Calu-3 is an immortalised cell line obtained from lung adenocarcinoma and has been extensively used in the study of formulations designed for either nasal or pulmonary drug delivery, as it is considered a model of the epithelium of both regions (Casettari, Vllasaliu, Mantovani, Howdle, Stolnik & Illum, 2010; Grainger, Greenwell, Lockley, Martin & Forbes, 2006; Zhu, Chidekel & Shaffer, 2010). Importantly, Calu-3 cells form tight junctions *in vitro* (Winton et al., 1998) and, under suitable culture conditions, exhibit *in vivo*-like barrier properties (Grainger, Greenwell, Lockley, Martin & Forbes, 2006). A549 is a cell line representative of the alveolar epithelium, obtained from human alveolar adenocarcinoma, showing no ability to form functional tight junctions in culture (Forbes & Ehrhardt, 2005; Foster, Yazdanian & Audus, 2001; Winton et al., 1998). Consequently, it cannot be used in studies of the epithelial barrier integrity, although this does not prevent their use in cytotoxicity studies.

3.5.1. Evaluation of metabolic activity (MTT assay)

The MTT assay provides an evaluation of the cell metabolic activity upon exposure to the samples and has been used very frequently in the assessment of drug delivery carriers (Rodrigues, Dionísio, Remuñán-López & Grenha, 2012). It evaluates the ability of the cells to reduce the MTT reagent to tetrazolium salts, an action that is dependent on mitochondrial metabolism. A reduction of cellular metabolic activity is generally accepted as an early indicator of cellular damage (Scherließ, 2011).

In this work, A549 and Calu-3 cells were cultured and exposed to different concentrations of nanoparticles and raw materials for both a short (3h) and a more prolonged period (24h). The exposure for 3h did not lead to significant decrease in cell viability, with values remaining close to 90-100% in all cases. The only exception occurred for A549 cells exposed to

589 chitosan (data not shown), an effect commented later. In contrast, the prolongation of
 590 exposure up to 24h induces some variability on cell viability. In this manner, for the contact
 591 time of 24h a factorial design was approached to examine the effect of sample type (raw
 592 materials/carrier formulations; X_1) and concentration (X_2) on cell viability (Y), for each cell
 593 line. The two factors (X_1 , X_2) of the experimental design have three levels each, resulting in
 594 nine factor/level combinations.

595 Cell viability results obtained upon 24h exposure are depicted in Figures 4 (Calu-3 cells) and
 596 5 (A549 cells). For Calu-3 cells, an unbalanced FD was used in the group of raw materials
 597 and formulations. For the raw materials (Figure 4A), a significant effect ($p < 0.05$) was
 598 detected for each of the main factors (X_1 and X_2) and their interaction ($X_1 * X_2$). The most
 599 relevant observation is that TPP induced a greater decrease of cell viability as compared to
 600 CS and CRG ($p < 0.05$).

601 With respect to the formulations, the factorial experiment reveals that only X_1 (type of
 602 materials) and the two-way interaction $X_1 * X_2$ are statistically significant ($p < 0.05$). Although
 603 the lowest viability induced by raw materials was observed for the highest concentration of
 604 TPP (1.0 mg/mL, Figure 4A), cell viability upon contact with CS/CRG/TPP nanoparticles
 605 was above 95% in all instances (Figure 4B), no concentration-dependent effect being
 606 observed. In this manner, as a cell viability of 70% is the threshold beyond which a cytotoxic
 607 effect is considered to occur according to ISO 10993-5 (ISO, 2009), the observed effects are
 608 devoid of physiological relevance. This indicates that Calu-3 cells do not evidence a
 609 particular sensitivity to any of the tested samples, either raw materials or nanoparticle-based
 610 formulations, at the tested concentrations.

611 In A549 cells, a balanced FD of the raw materials showed a significant effect for both main
 612 factors (X_1 and X_2) and their interaction ($X_1 * X_2$). Among raw materials only CRG and TPP
 613 show a significant difference between the concentration levels ($p < 0.05$), cell viability

614 decreasing with increasing concentrations, particularly at the concentration of 1 mg/mL
 615 (Figure 5A). Nevertheless, cell viabilities were higher than 70% in **all conditions tested for**
 616 **both polymers**. The most deleterious effect was observed for chitosan ($p < 0.05$), which
 617 induced high cytotoxicity, as was also detected upon 3h, even at the lower concentration of
 618 0.1 mg/mL.

619 **The different response of both cell lines to CS exposure (in Calu-3 cells no viability decrease**
 620 **was observed)** is most probably related with the different structures evidenced by Calu-3 and
 621 A549 cells in culture and with their sensitivity to pH alterations. In fact, while Calu-3 cells
 622 are rounder, A549 cells grow according to a more extended profile, as can be easily seen in
 623 ATCC webpage (Collection, 2012). Chitosan used in this work is a base and, therefore, is
 624 dissolved in acetic acid (**pH around 3.2**) to assemble the nanoparticles. The same solution was
 625 used in the assay, although it was previously diluted with CCM. Upon addition to the cell
 626 layer, it was observed on the microscope that A549 cells begin to detach, an effect not
 627 perceived for Calu-3 cells. Therefore, the cells are no longer attached to the plate and are
 628 easily removed during the washing steps even before the MTT reagent **is added, not**
 629 **permitting** a reliable measure of the metabolic activity. This indicates that these results should
 630 be taken with precaution. Importantly, although there are not many studies testing chitosan
 631 solutions in A549 cells, the literature reports an absence of overt toxicity of the polymer in
 632 this cell line at concentrations similar to those used in this study, although a different chitosan
 633 polymer (regarding molecular weight and salt) was used (Huang, Khor & Lim, 2004).

634 The behaviour of A549 cells regarding the tested drug delivery systems was generally similar
 635 to that of Calu-3 cells, evidencing a very favourable profile. The statistical details of the FD
 636 showed that both main effects (X_1 and X_2) and their interaction ($X_1 * X_2$) are significant ($p <$
 637 0.05), the interaction being appreciated in Figure 5B. **Although with slight variations, cell**

viability was above 80% in all cases. Nevertheless, it is observed that microencapsulated nanoparticles are those causing the more amenable effect.

As a whole, these results indicate that neither the loading of BSA in nanoparticles nor the microencapsulation process induced physiologically relevant alterations on the response of the cells to the systems. No studies regarding the effect of CS/CRG/TPP nanoparticles on cell viability were reported before, thus hampering the comparison of the present results with others. The most similar studies reported the absence of overt toxicity of either CS/CRG nanoparticles in L929 fibroblasts at the concentration of 1 mg/mL (Grenha et al., 2010) or CS/TPP nanoparticles in Calu-3 and A549 cells (Grenha et al., 2007), while several other formulations of CS-based nanoparticles were also reported to not induce a cytotoxic effect in different cell lines (Caban, Capan, Couvreur & Dalkara, 2012; Dionísio, Cordeiro, Remuñán-López, Seijo, Rosa da Costa & Grenha, 2013; Oliveira, Silva, Bitoque, Silva & Rosa da Costa, 2013).

The findings obtained in this work for all nanoparticle-based formulations in both respiratory cell lines are considered good indicators of biocompatibility. However, the evaluation of a biocompatibility profile demands the use of complementary assays that assess other aspects of cell response, which is certainly of importance to establish a final tendency.

3.5.2. Determination of inflammatory response

In parallel with the evaluation of cell viability, the ability of the carriers to induce an inflammatory response upon contact with the cells has also been used as an indicator of biocompatibility (Lim, Yaacob, Ismail & Halim, 2010; McCarthy, Inkielewicz-Śtěpniak, Corbalan & Radomski, 2012; Mura et al., 2011). The evaluation of such a response might be performed by quantifying the release of inflammatory markers by the cells upon exposure to the drug delivery systems. IL-6 and IL-8 are two cytokines suitable for this end, as IL-6 is

responsible for neutrophil activation and IL-8 is a chemotactic agent for inflammatory cells (Lewis & McGee, 1992).

In this assay, the effect of the three nanoparticle-based carriers (CS/CRG/TPP nanoparticles, BSA-loaded nanoparticles and microencapsulated nanoparticles) was evaluated regarding the induction of an inflammatory phenotype in the Calu- 3 cells by means of the determination of released IL- 6 and IL- 8. The obtained results are depicted in Figure 6. The assessment was conducted upon 24h exposure to the drug delivery systems (1.0 mg/mL) using LPS as a positive control (10 µg/mL) and CCM as a negative control. The amount of cytokines released in response to CCM was considered 100% and all the other results are presented with respect to that value. As expected, a basal concentration of cytokines in the supernatant was detected in control cells (incubated only with CCM) (Grainger, Greenwell, Martin & Forbes, 2009; Mura et al., 2011) and IL- 8 was secreted at a higher concentration than IL- 6 (Mura et al., 2011; Zhu, Chidekel & Shaffer, 2010).

Remarkably, no significant effect was elicited by either CS/CRG/TPP nanoparticles or the microencapsulated counterparts as compared with untreated cells. Additionally, IL- 8 and IL- 6 levels did not differ between the treatment groups, indicating an absence of effect of the microencapsulation process.

Nanoparticles produced without TPP were also tested as controls, evidencing a response very similar to that of CS/CRG/TPP nanoparticles, which indicates that the inclusion of TPP does not induce a different effect. Finally, a significant increase in the release of both cytokines was only found upon the exposure to LPS (approximately 220% for IL-8 and 360% for IL-6; $p < 0.05$). This effect was expected, as LPS is known to induce an inflammatory response, corresponding to reported findings (Alfaro-Moreno et al., 2009; Mura et al., 2011).

3.5.3. Evaluation of epithelial integrity

688 Intercellular structures are crucial for epithelial development and function. Tight junctions are
689 the most restrictive intercellular junctions, forming a continuous band which completely
690 circumvents the periphery of epithelial cells at the mucosal surface (Matter & Balda, 2003).
691 As mentioned above, and contrary to A549 cells, Calu-3 cells have the ability to form tight
692 junctions *in vitro*, displaying the properties characteristic of an epithelial barrier (Grainger,
693 Greenwell, Lockley, Martin & Forbes, 2006).
694 In this study, Calu-3 cells were exposed to CS/CRG/TPP nanoparticles at 1 mg/mL to
695 determine the effect of the drug delivery system on the epithelial integrity, as a
696 complementary biocompatibility indicator. The TER was continuously monitored for 48h and
697 the results are shown in Figure 7. It is observed that the TER did not suffer significant
698 alterations after treatment with nanoparticles over a period of 48h. Although not statistically
699 significant, a slight decrease of approximately 10% with respect to control was observed at
700 early time points, but at 4h the TER reached 100% again and surpassed that value at later
701 times.
702 No similar results were found on Calu-3 cells, but an increase in TER has been reported in
703 Caco-2 cells (intestinal epithelium) as a response of the cells to an external stimulation
704 (Klingberg, Pedersen, Cencic & Budde, 2005; Sonnier, Bailey, Pritts & Lentsch, 2011), in
705 one case being associated with a response to an inflammatory stimulus (Sonnier, Bailey,
706 Pritts & Lentsch, 2011). Nevertheless, in our study this correlation cannot be established as
707 no significant inflammatory response was obtained upon contact with the nanoparticles, as
708 evidenced above. On the other side, although a decrease in TER was observed in many
709 occasions with chitosan solutions in several epithelial cell lines including the Calu-3 (Florea,
710 Thanou, Junginger & Borchard, 2006; Portero, Remuñán-López & Nielsen, 2002; Smith,
711 Wood & Dornish, 2004), an absence of effect of chitosan-based nanoparticles is also
712 described in the literature (Behrens, Pena, Alonso & Kissel, 2002; Grenha et al., 2007).

Therefore, this observation comprises an extra indication on the biocompatibility of CS/CRG/TPP nanoparticles.

Although the obtained results are good indicators that no deleterious effects are to be expected for short-term contact of the pulmonary or nasal mucosa with the developed nanocarriers, it is important to recall that the effects of a prolonged administration also require attention. In this regard, the rapid mucus turnover in the nasal mucosa certainly prevents nanoparticle accumulation, but that will not be the case in pulmonary delivery, where this concern is unavoidable. The consequences of long-term exposition to particulates are quite unknown (Dombu & Betbeder, 2013), but a retention half-time of approximately 700 days was reported for humans (Oberdörster, Oberdörster & Oberdörster, 2005). With their ability to evade specific defence mechanisms, once in the lung nanoparticles might either accumulate in the lung tissue, causing inflammation that can trigger more severe effects, or they can translocate for extrapulmonary regions, which is also a matter of great concern. This clearly evidences the urgent need of extra studies addressing the raised concerns, which are lacking in the literature. It is of utmost relevance to determine the fate of nanoparticles when in contact with respiratory epithelia, thus enabling an adequate risk assessment and, hopefully, the establishment of nanoparticles in clinic to become a reality.

4. Conclusion

This work demonstrates the suitability of CS/CRG/TPP nanoparticles as carriers for an application in pulmonary and nasal drug delivery, with a particular emphasis on their biocompatibility potential. Apart from the ability to associate a model macromolecule, BSA, the nanoparticles demonstrated to be stable in presence of an amount of lysozyme simulating *in vivo* conditions. The nanocarriers also evidenced stability upon freeze-drying in presence of glucose or sucrose, used as cryoprotectants. The protein-loaded nanoparticles were

successfully incorporated in microspheres by means of a spray-drying process, resulting in a dry powder with suitable properties for lung delivery. Moreover, the developed carriers exhibited low or negligible toxicity in contact with two respiratory cell lines representing both the nasal and pulmonary epithelium, as demonstrated by the effects on cell metabolic activity and transepithelial electrical resistance. These findings were reinforced by the observation of no inflammatory response generated upon 24h of exposure of the cells to the carriers. Altogether, these results are an encouraging indicator of the biocompatibility and safety of CS/CRG/TPP nanoparticles regarding nasal and pulmonary delivery, making them suitable candidates for these applications.

5. Acknowledgements

This work was supported by National Portuguese funding through FCT - Fundação para a Ciência e a Tecnologia, projects PTDC/SAU-FCF/100291/2008, PTDC/DTP-FTO/0094/2012 and PEst-OE/EQB/LA0023/2013, as well as by the Spanish Government (ISCIII, Acción Estratégica de Salud, PS09/00816). Research of Clara Cordeiro is supported by FCT project PEst-OE/MAT/UI0006/2014. Susana Rodrigues acknowledges her PhD scholarship from FCT (reference SFRH/BD/52426/2013), as well as a ShareBiotech mobility grant.

Reference list

- Abdelwahed, W., Degobert, G., Stainmesse, S., & Fessi, H. (2006). Freeze-drying of nanoparticles: Formulation, process and storage considerations. *Advanced Drug Delivery Reviews*, 58(15), 1688-1713.
- Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J., & Forrest, M. L. (2009). Effects of nanomaterial physicochemical properties on in vivo toxicity. *Advanced Drug Delivery Reviews*, 61(6), 457-466.

764 Al-Qadi, S., Grenha, A., Carrión-Recio, D., Seijo, B., & Remuñán-López, C. (2012). Microencapsulated
 765 chitosan nanoparticles for pulmonary protein delivery: In vivo evaluation of insulin-loaded
 766 formulations. *Journal of Controlled Release*, 157, 383-390.

767 Alfaro-Moreno, E., Torres, V., Miranda, J., Martínez, L., García-Cuellar, C., Nawrot, T. S.,
 768 Vanaudenaerde, B., Hoet, P., Ramírez-López, P., Rosas, I., Nemery, B., & Osornio-Vargas, A. R. (2009).
 769 Induction of IL-6 and inhibition of IL-8 secretion in the human airway cell line Calu-3 by urban
 770 particulate matter collected with a modified method of PM sampling. *Environmental Research*,
 771 109(5), 528-535.

772 Behrens, I., Pena, A. I., Alonso, M. J., & Kissel, T. (2002). Comparative uptake studies of bioadhesive
 773 and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on
 774 particle adsorption and transport. *Pharmaceutical Research*, 19, 1185-1193.

775 Beirowski, J., Inghelbrecht, S., Arien, A., & Gieseler, H. (2011). Freeze drying of nanosuspensions, 2:
 776 the role of the critical formulation temperature on stability of drug nanosuspensions and its practical
 777 implication on process design. *Journal of Pharmaceutical Sciences*, 100, 4471-4481.

778 Beirowski, J., Inghelbrecht, S., Arien, A., & Gieseler, H. (2012). Freeze drying of nanosuspensions,
 779 part 3: investigation of factors compromising storage stability of highly concentrated drug
 780 nanosuspensions. *Journal of Pharmaceutical Sciences*, 101, 354-362.

781 Bernkop-Schnürch, A., Weithaler, A., Albrecht, K., & Greimel, A. (2006). Thiomers: Preparation and in
 782 vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. *International Journal of*
 783 *Pharmaceutics*, 317(1), 76-81.

784 Bogataj, M., Vovk, T., Kerec, M., Dimnik, A., scaron, Grabnar, I., & Mrhar, A. (2003). The correlation
 785 between zeta potential and mucoadhesion strength on pig vesical mucosa. *Biological and*
 786 *Pharmaceutical Bulletin*, 26(5), 743-746.

787 Bosquillon, C., Lombry, C., Préat, V., & Vanbever, R. (2001). Influence of formulation excipients and
 788 physical characteristics of inhalation dry powders on their aerosolization performance. *Journal of*
 789 *Controlled Release*, 70(3), 329-339.

790 Caban, S., Capan, Y., Couvreur, P., & Dalkara, T. (2012). Preparation and characterization of
791 biocompatible chitosan nanoparticles for targeted brain delivery of peptides. In S. Skaper.
792 *Neurotrophic Factors* pp. 321-332). London: Humana Press.

793 Carmichael, J., DeGraff, W., Gazdar, A., Minna, J., & Mitchell, J. (1987). Evaluation of a tetrazolium-
794 based semiautomated colorimetric assay: assessment of chemosensitivity testing. *Cancer Research*,
795 47, 936-942.

796 Carvalho, E. L. S., Grenha, A., Remunan-Lopez, C., Alonso, M. J., & Seijo, B. (2009). Mucosal delivery
797 of liposome-chitosan nanoparticle complexes. *Methods in Enzymology Liposomes, Pt G*, 465, 289-
798 312.

799 Carvalho, F., Bruschi, M., Evangelista, R., & Gremião, M. (2010). Mucoadhesive drug delivery
800 systems. *Brazilian Journal of Pharmaceutical Sciences*, 46(1), 1-17.

801 Casettari, L., Vllasaliu, D., Mantovani, G., Howdle, S. M., Stolnik, S., & Illum, L. (2010). Effect of
802 PEGylation on the toxicity and permeability enhancement of chitosan. *Biomacromolecules*, 11(11),
803 2854-2865.

804 Chacón, M., Molpeceres, J., Berges, L., Guzmán, M., & Aberturas, M. R. (1999). Stability and freeze-
805 drying of cyclosporine loaded poly(D,L lactide–glycolide) carriers. *European Journal of*
806 *Pharmaceutical Sciences*, 8(2), 99-107.

807 Collection, A. T. C. (2012). A549 (ATCC® CCL-185™)

808 de la Fuente, M., Seijo, B., & Alonso, M. J. (2008). Novel hyaluronan-based nanocarriers for
809 transmucosal delivery of macromolecules. *Macromolecular Bioscience*, 8(5), 441-450.

810 Desai, M. P., Labhasetwar, V., Amidon, G. L., & Levy, R. J. (1996). Gastrointestinal uptake of
811 biodegradable microparticles: effect of particle size. *Pharmaceutical Research*, 13(12), 1838-1845.

812 Dionísio, M., Cordeiro, C., Remuñán-López, C., Seijo, B., Rosa da Costa, A., & Grenha, A. (2013).
813 Pullulan-based nanoparticles as carriers for transmucosal protein delivery. *European Journal of*
814 *Pharmaceutical Sciences*, 50, 102-113.

815 Dombu, C. Y., & Betbeder, D. (2013). Airway delivery of peptides and proteins using nanoparticles.
816 *Biomaterials*, 34(2), 516-525.

817 Du, H., Cai, X., & Zhai, G. (2014). Advances in the targeting molecules modified chitosan-based
818 nanoformulations. *Current Drug Targets*, 14(9), 1034-1052.

819 El-Gibaly, I. (2002). Development and in vitro evaluation of novel floating chitosan microcapsules for
820 oral use: comparison with non-floating chitosan microspheres. *International Journal of*
821 *Pharmaceutics*, 249(1–2), 7-21.

822 Florea, B. I., Thanou, M., Junginger, H. E., & Borchard, G. (2006). Enhancement of bronchial
823 octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation.
824 *Journal of Controlled Release*, 110(2), 353-361.

825 Forbes, B., & Ehrhardt, C. (2005). Human respiratory epithelial cell culture for drug delivery
826 applications. *European Journal of Pharmaceutics and Biopharmaceutics*, 60(2), 193-205.

827 Foster, K. A., Avery, M. L., Yazdanian, M., & Audus, K. L. (2000). Characterization of the Calu-3 cell
828 line as a tool to screen pulmonary drug delivery. *International Journal of Pharmaceutics*, 208(1–2), 1-
829 11.

830 Foster, K. A., Yazdanian, M., & Audus, K. L. (2001). Microparticulate uptake mechanisms of in-vitro
831 cell culture models of the respiratory epithelium. *Journal of Pharmacy and Pharmacology*, 53(1), 57-
832 66.

833 Freixeiro, P., Diéguez-Casal, E., Costoya, L., Seijo, B., Ferreirós, C. M., Criado, M. T., & Sánchez, S.
834 (2013). Study of the stability of proteoliposomes as vehicles for vaccines against *Neisseria*
835 *meningitidis* based on recombinant porin complexes. *International Journal of Pharmaceutics*, 443(1–
836 2), 1-8.

837 Gaspar, R., & Duncan, R. (2009). Polymeric carriers: Preclinical safety and the regulatory implications
838 for design and development of polymer therapeutics. *Advanced Drug Delivery Reviews*, 61(13), 1220-
839 1231.

840 Goycoolea, F. M., Lollo, G., Remunan-Lopez, C., Quaglia, F., & Alonso, M. J. (2009). Chitosan-alginate
841 blended nanoparticles as carriers for the transmucosal delivery of macromolecules.
842 *Biomacromolecules*, 10(7), 1736-1743.

843 Grainger, C., Greenwell, L., Lockley, D., Martin, G., & Forbes, B. (2006). Culture of Calu-3 cells at the
844 air interface provides a representative model of the airway epithelial barrier. *Pharmaceutical*
845 *Research*, 23(7), 1482-1490.

846 Grainger, C. I., Greenwell, L. L., Martin, G. P., & Forbes, B. (2009). The permeability of large
847 molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory
848 mucosa. *European Journal of Pharmaceutics and Biopharmaceutics*, 71(2), 318-324.

849 Grenha, A. (2012). Chitosan nanoparticles: a survey of preparation methods. *Journal of Drug*
850 *Targeting*, 20(4), 291-300.

851 Grenha, A., Gomes, M. E., Rodrigues, M., Santo, V. E., Mano, J. F., Neves, N. M., & Reis, R. L. (2010).
852 Development of new chitosan/carrageenan nanoparticles for drug delivery applications. *Journal of*
853 *Biomedical Materials Research Part A*, 92A(4), 1265-1272.

854 Grenha, A., Grainger, C. I., Dailey, L. A., Seijo, B., Martin, G. P., Remuñán-López, C., & Forbes, B.
855 (2007). Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. *European*
856 *Journal of Pharmaceutical Sciences*, 31(2), 73-84.

857 Grenha, A., Seijo, B., & Remuñán-López, C. (2005). Microencapsulated chitosan nanoparticles for
858 lung protein delivery. *European Journal of Pharmaceutical Sciences*, 25, 427-437.

859 Gupta, H., & Sharma, A. (2009). Recent trends in protein and peptide drug delivery systems. *Asian*
860 *Journal of Pharmaceutics*, 3, 69-75.

861 Hirsjärvi, S., Peltonen, L., & Hirvonen, J. (2009). Effect of sugars, surfactant, and tangential flow
862 filtration on the freeze-drying of poly(lactic acid) nanoparticles. *AAPS PharmSciTech*, 10(2), 488-494.

863 Hoppentocht, M., Hagedoorn, P., Frijlink, H. W., & de Boer, A. H. (2014). Developments and
864 strategies for inhaled antibiotic drugs in tuberculosis therapy: A critical evaluation. *European Journal*
865 *of Pharmaceutics and Biopharmaceutics*, 86(1), 23-30.

866 Huang, M., Khor, E., & Lim, L.-Y. (2004). Uptake and cytotoxicity of chitosan molecules and
867 nanoparticles: Effects of molecular weight and degree of deacetylation. *Pharmaceutical Research*,
868 21(2), 344-353.

869 ISO (2009). Biological evaluation of medical devices Part 5: Tests for in vitro cytotoxicity. In I. O. f.
870 Standardization. 10993-5.

871 Jani, P., Halbert, G., Langridge, J., & Florence, A. (1990). Nanoparticle uptake by the rat
872 gastrointestinal mucosa: quantitation and particle size dependency. *Journal of Pharmacy and*
873 *Pharmacology*, 42(12), 821-826.

874 Klingberg, T. D., Pedersen, M. H., Cencic, A., & Budde, B. B. (2005). Application of measurements of
875 transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic
876 activity. *Applied and Environmental Microbiology*, 71(11), 7528-7530.

877 Konstan, M., Chen, P., Sherman, J., Thomassen, M., Woodm, R., & Boat, T. (1981). Huamn lung
878 lysozyme: sources and properties. *American Reviews of Respiratory Disease*, 123, 120-124.

879 Kumar, G., Shafiq, N., & Malhotra, S. (2012). Drug-loaded PLGA nanoparticles for oral administration:
880 fundamental issues and challenges ahead. *Critical Reviews in Therapeutic Drug Carrier Systems*,
881 29(2), 149-182.

882 Labiris, N., Holbrook, A., Chrystyn, H., Macleod, S., & Newhouse, M. (1999). Dry powder versus
883 intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. *American Journal of*
884 *Respiratory and Critical Care Medicine*, 160, 1711-1716.

885 Lehr, C.-M., Bouwstra, J. A., Schacht, E. H., & Junginger, H. E. (1992). In vitro evaluation of
886 mucoadhesive properties of chitosan and some other natural polymers. *International Journal of*
887 *Pharmaceutics*, 78, 43-48.

888 Lewis, C., & McGee, J. D. (1992). *The macrophage*. Oxford: IRL Press.

889 Li, S., Patapoff, T., Overcashier, D., Hsu, C., Nguyen, T., & Borchardt, R. (1996). Effects of reducing
890 sugars on the chemical stability of human relaxin in the lyophilized state. *Journal of Pharmaceutical*
891 *Sciences*, 85(8), 873-877.

892 Li, Y.-Z., Sun, X., Gong, T., Liu, J., Zuo, J., & Zhang, Z.-R. (2010). Inhalable microparticles as carriers for
893 pulmonary delivery of thymopentin-loaded solid lipid nanoparticles. *Pharmaceutical Research*, 27(9),
894 1977-1986.

895 Lim, C. K., Yaacob, N. S., Ismail, Z., & Halim, A. S. (2010). In vitro biocompatibility of chitosan porous
896 skin regenerating templates (PSRTs) using primary human skin keratinocytes. *Toxicology in Vitro*,
897 24(3), 721-727.

898 Malafaya, P., Silva, G., & Reis, R. (2007). Natural-origin polymers as carriers and scaffolds for
899 biomolecules and cell delivery in tissue engineering application. *Advanced Drug Delivery Reviews*, 59,
900 207-233.

901 Marttin, E., Schipper, N. G. M., Verhoef, J. C., & Merkus, F. W. H. M. (1998). Nasal mucociliary
902 clearance as a factor in nasal drug delivery. *Advanced Drug Delivery Reviews*, 29(1-2), 13-38.

903 Matter, K., & Balda, M. (2003). Functional analysis of tight junctions. *Methods*, 30, 228-234.

904 McCarthy, J., Inkielewicz-Stępnia, I., Corbalan, J. J., & Radomski, M. W. (2012). Mechanisms of
905 toxicity of amorphous silica nanoparticles on human lung submucosal cells in vitro: Protective effects
906 of fisetin. *Chemical Research in Toxicology*, 25(10), 2227-2235.

907 Mura, S., Hillaireau, H., Nicolas, J., Le Droumaguet, B., Gueutin, C., Zanna, S., Tsapis, N., & Fattal, E.
908 (2011). Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3
909 cells. *International Journal of Nanomedicine*, 6(2591-2605).

910 Muzzarelli, R. (1997). Human enzymatic activities related to the therapeutic administration of chitin
911 derivatives. *Cellular and Molecular Life Sciences*, 53, 131-140.

912 Nahar, K., Gupta, N., Gauvin, R., Absar, S., Patel, B., Gupta, V., Khademhosseini, A., & Ahsan, F.
913 (2013). In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of
914 inhaled pharmaceuticals. *European Journal of Pharmaceutical Sciences*, 49(5), 805-818.

915 Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005). Nanotoxicology: An emerging discipline
916 evolving from studies of ultrafine particles. *Environmental and Health Perspectives*, 113, 823-839.

917 Oliveira, A., Silva, A., Bitoque, D., Silva, G., & Rosa da Costa, A. (2013). Transfection efficiency of
 918 chitosan and thiolated chitosan in retinal pigment epithelium cells: A comparative study. *Journal of*
 919 *Pharmacy and Bioallied Sciences*, 5, 111-118.

920 Oyarzun-Ampuero, F., Brea, J., Loza, M., Torres, D., & Alonso, M. J. (2009). Chitosan-hyaluronic acid
 921 nanoparticles loaded with heparin for the treatment of asthma. *International Journal of*
 922 *Pharmaceutics*, 381, 122-129.

923 Pinto Reis, C., Neufeld, R., Ribeiro, A., & Veiga, F. (2006). Nanoencapsulation II. Biomedical
 924 applications and current status of peptide and protein nanoparticulate delivery systems.
 925 *Nanomedicine: Nanotechnology, Biology, and Medicine*, 2, 53-65.

926 Portero, A., Remuñán-López, C., & Nielsen, H. M. (2002). The potential of chitosan in enhancing
 927 peptide and protein absorption across the TR146 cell culture model — An in vitro model of the
 928 buccal epithelium. *Pharmaceutical Research*, 19(2), 169-174.

929 Pourshahab, P. S., Gilani, K., Moazeni, E., Eslahi, H., Fazeli, M. R., & Jamalifar, H. (2011). Preparation
 930 and characterization of spray dried inhalable powders containing chitosan nanoparticles for
 931 pulmonary delivery of isoniazid. *Journal of Microencapsulation*, 28(7), 605-613.

932 Rodrigues, S., Dionísio, M., Remuñán-López, C., & Grenha, A. (2012). Biocompatibility of chitosan
 933 carriers with application in drug delivery. *Journal of Functional Biomaterials*, 3, 615-641.

934 Rodrigues, S., Rosa da Costa, A., & Grenha, A. (2012). Chitosan/carrageenan nanoparticles: Effect of
 935 cross-linking with tripolyphosphate and charge ratios. *Carbohydrate Polymers*, 89, 282-289.

936 Rogueda, P., & Traini, D. (2007). The nanoscale in pulmonary delivery. Part 1: deposition, fate,
 937 toxicology and effects. *Expert Opinion on Drug Delivery*, 4(6), 595-606.

938 Sameti, M., Bohr, G., Ravi Kumar, M. N. V., Kneuer, C., Bakowsky, U., Nacken, M., Schmidt, H., &
 939 Lehr, C. M. (2003). Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene
 940 delivery. *International Journal of Pharmaceutics*, 266(1–2), 51-60.

941 Sandri, G., Bonferoni, M., Rossi, S., Ferrari, F., Boselli, C., & Caramella, C. (2010). Insulin-loaded
 942 nanoparticles based on N-trimethyl chitosan: In vitro (Caco-2 model) and ex vivo (excised rat

943 jejunum, duodenum, and ileum) evaluation of penetration enhancement properties. *AAPS*
 944 *PharmSciTech*, 11(1), 362-371.

945 Scherließ, R. (2011). The MTT assay as tool to evaluate and compare excipient toxicity in vitro on
 946 respiratory epithelial cells. *International Journal of Pharmaceutics*, 411(1–2), 98-105.

947 Smith, J., Wood, E., & Dornish, M. (2004). Effect of chitosan on epithelial cell tight junctions.
 948 *Pharmaceutical Research*, 21(1), 43-49.

949 Sonnier, D. I., Bailey, S. R., Pritts, T. A., & Lentsch, A. B. (2011). TNF- α induced vectorial secretion of
 950 IL-8 corresponds to development of transepithelial electrical resistance in Caco-2 cells.
 951 *Gastroenterology*, 140(5), S-1044-S-1045.

952 Sung, J. C., Pulliam, B. L., & Edwards, D. A. (2007). Nanoparticles for drug delivery to the lungs.
 953 *Trends in biotechnology*, 25(12), 563-570.

954 Umrethia, M., Kett, V. L., Andrews, G. P., Malcolm, R. K., & Woolfson, A. D. (2010). Selection of an
 955 analytical method for evaluating bovine serum albumin concentrations in pharmaceutical polymeric
 956 formulations. *Journal of Pharmaceutical and Biomedical Analysis*, 51(5), 1175-1179.

957 Vauthier, C., & Bouchemal, K. (2009). Methods for the preparation and manufacture of polymeric
 958 nanoparticles. *Pharmaceutical Research*, 26(5), 1025-1058.

959 Vila, A., Sánchez, A., Tobío, M., Calvo, P., & Alonso, M. J. (2002). Design of biodegradable particles for
 960 protein delivery. *Journal of Controlled Release*, 78(1–3), 15-24.

961 Wang, W. (2000). Lyophilization and development of solid protein pharmaceuticals. *International*
 962 *Journal of Pharmaceutics*, 203(1–2), 1-60.

963 Williams, D. F. (2008). On the mechanisms of biocompatibility. *Biomaterials*, 29(20), 2941-2953.

964 Winton, H., Wan, H., Cannell, M., Gruenert, D., Thompson, P., Garrod, D., Stewart, G., & Robinson, C.
 965 (1998). Cell lines of pulmonary and non-pulmonary origin as tools to study the effects of house dust
 966 mite proteinases on the regulation of epithelial permeability. *Clinical & Experimental Allergy*, 28(10),
 967 1273-1285.

968 Wu, L., Zhang, J., & Watanabe, W. (2011). Physical and chemical stability of drug nanoparticles.
969 *Advanced Drug Delivery Reviews*, 63(6), 456-469.

970 Zhu, Y., Chidekel, A., & Shaffer, T. (2010). Cultured human airway epithelial cells (Calu-3): A model of
971 human respiratory function, structure, and inflammatory responses. *Critical Care Research and*
972 *Practice*, 2010, 1-8.

973 Zorzi, G. K., Párraga, J. E., Seijo, B., & Sánchez, A. (2011). Hybrid nanoparticle design based on
974 cationized gelatin and the polyanions dextran sulfate and chondroitin sulfate for ocular gene
975 therapy. *Macromolecular Bioscience*, 11(7), 905-913.

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

Figure legends

Figure 1. A) TEM microphotograph of BSA-loaded CS/CRG/TPP (4/1/1, w/w)

nanoparticles; B) SEM microphotograph of microspheres composed of

mannitol/nanoparticles = 80/20 (w/w).

Figure 2. Size evolution as a function of time upon incubation of CS/CRG/TPP nanoparticles

(□) mass ratio 4/1/0 and (■) mass ratio 4/1/1, with A) 0.2 mg/mL and B) 0.8 mg/mL

lysozyme, at 37 °C (mean ± SD, $n = 3$).

Figure 3. Size variation of CS/CRG/TPP nanoparticles upon freeze-drying at different

concentrations, in presence of 5% or 10% sucrose, trehalose, lactose and glucose, and further

reconstitution in water (hydrodynamic diameter of nanoparticles before (Di) and after (Df)

freeze-drying). Results represent mean ± SD ($n = 3$); *** indicates formation of precipitate.

Figure 4. Calu-3 cells viability measured by the MTT assay after 24h exposure to raw

materials (A - CS: chitosan, CRG: carrageenan, TPP: tripolyphosphate) and nanoparticle-

based formulations (B - NP: nanoparticles, BSA-NP: BSA-loaded nanoparticles, Micro NP:

microencapsulated nanoparticles). Data represent mean ± SEM ($n = 3$, six replicates per

experiment at each concentration).

Figure 5. A549 cells viability measured by the MTT assay after 24h exposure to raw

materials (A - CS: chitosan, CRG: carrageenan, TPP: tripolyphosphate) and nanoparticle-

based formulations (B - NP: nanoparticles, BSA-NP: BSA-loaded nanoparticles, Micro NP:

microencapsulated nanoparticles). Data represent mean ± SEM ($n = 3$, six replicates per

experiment at each concentration).

Figure 6. IL-6 (grey bars) and IL-8 (white bars) secretion by Calu-3 cells exposed for 24h to CS/CRG and CS/CRG/TPP nanoparticles, microNP and lipopolysaccharide. Data showed as % of release comparing to control (mean $\pm$ SD, $n = 3$).

Figure 7 - Transepithelial electrical resistance (TER) of Calu-3 cell layers upon incubation with CS/CRG/TPP nanoparticle suspension (1.0 mg/mL). Data represent mean $\pm$ SEM of three experiments ($n = 3$ per experiment).

Table 1. Physicochemical properties, production yield and encapsulation data of BSA-loaded CS/CRG/TPP (4/1/1, w/w) nanoparticles (mean $\pm$ SD, $n = 3$).

CS/CRG/TPP formulation	Size (nm)	ζ Potential (mV)	Production yield (%)	Encapsulation efficiency (%)	Loading capacity (%)
4/1/0 loaded	226 $\pm$ 35	+27 $\pm$ 5	15 $\pm$ 2	51 $\pm$ 12	70 $\pm$ 18
4/1/1 loaded	327 $\pm$ 32	+40 $\pm$ 5	30 $\pm$ 2	48 $\pm$ 8	27 $\pm$ 5

Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7